Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $931.07M
- Beta
- 0.00
Volume 0.30M
Average 0.43M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$19.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
No data available for this stock.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Spyre Therapeutics, Inc. NASDAQ:SYRE | $9.88B | $104.00 | Not rated | -171.1 | +289.25% |
Protagonist Therapeutics, Inc. NASDAQ:PTGX | $8.55B | $130.95 | Undervalued | -64.2 | +47.73% |
Oruka Therapeutics, Inc. NASDAQ:ORKA | $7.15B | $105.35 | Not rated | -33.9 | +250.89% |
AnaptysBio, Inc. NASDAQ:ANAB | $1.38B | $46.25 | Overvalued | -59.7 | +84.88% |
Alumis Inc. Common Stock NASDAQ:ALMS | $724.84M | $5.60 | Not rated | -12.2 | -24.49% |
Aclaris Therapeutics, Inc. NASDAQ:ACRS | $621.76M | $3.92 | Not rated | -8.2 | +35.74% |
AgomAb Therapeutics N.V. American Depositary Shares NASDAQ:AGMB | $313.22M | $6.36 | Not rated | -7.1 | — |
Immunic, Inc. NASDAQ:IMUX | $102.61M | $7.52 | Not rated | -4.1 | -3.55% |
Continue the stock analysis
Jump to another research area for this company.